Aptevo Therapeutics Inc. (APVO) analyst actions
Rating and price-target actions on APVO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the APVO overview →
1 measured APVO analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated | Press release | +2.25% | -8.57% |
Keep exploring
More APVO: earnings → · SEC filings → · APVO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | 320 | -0.12% | 42% |
| Viking Therapeutics, Inc. (VKTX) | 319 | -0.60% | 43% |
| MATEON THERAPEUTICS (MATN) | 318 | 0.00% | 35% |
| Senseonics Holdings, Inc. (SENS) | 318 | -0.44% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.